Case studies
Theranos Lessons for Founders, Boards and Investors
Theranos is one of the best-documented cases of a private startup that, according to the SEC and the Department of Justice, told investors things its operations did not support. This case study of the company sets out the dated facts from those public records first, then a separate section of editorial lessons on governance, due diligence and transparency toward investors.
Key facts at a glance
| Item | Documented fact | Source |
|---|---|---|
| Capital raised from investors | More than $700 million | SEC press release 2018-41, March 14, 2018 |
| 2014 revenue projection | More than $100 million | SEC, March 2018 |
| 2014 revenue the SEC says was actually generated | A little more than $100,000 | SEC, March 2018 |
| Holmes civil penalty (settled, no admission) | $500,000 | SEC, March 2018 |
| Officer and director bar (public companies) | 10 years | SEC, March 2018 |
| Shares Holmes agreed to return | 18.9 million | SEC, March 2018 |
| Criminal indictment | June 14, 2018 | DOJ, Northern District of California |
| Holmes verdict | January 3, 2022 | DOJ, Northern District of California |
| Holmes sentence | 135 months, imposed November 18, 2022 | DOJ, Northern District of California |
| Balwani sentence | 155 months, imposed December 7, 2022 | DOJ, Northern District of California |
What the SEC alleged in March 2018
On March 14, 2018, the SEC announced fraud charges against Theranos, its founder and chief executive Elizabeth Holmes, and its former president Ramesh “Sunny” Balwani. The agency said the company raised more than $700 million from investors.
The complaint made three central allegations about what investors were told:
- The device. Investors were led to believe a portable analyzer could run a wide range of tests from a few drops of blood. The SEC alleged it could complete only a small number of tests, and that most patient tests were run on modified or standard analyzers made by other companies.
- Military use. The company said its products had been deployed by the U.S. Department of Defense in Afghanistan and on medevac helicopters. The SEC alleged they had never been deployed by the Department of Defense.
- Revenue. Theranos projected more than $100 million in 2014 revenue. The SEC alleged the company generated a little more than $100,000 from operations that year.
Theranos and Holmes agreed to settle without admitting or denying the allegations, and the settlements were subject to court approval. Under the terms the SEC described, she paid a $500,000 penalty, accepted a 10-year bar from serving as an officer or director of a public company, and agreed to return 18.9 million shares. She also gave up voting control by converting her super-voting Class B shares into Class A shares. The SEC said that, under the liquidation preference, she would not profit until more than $750 million (assuming certain warrants were redeemed) had been returned to defrauded investors and other preferred shareholders. The SEC did not settle with Balwani and said it would litigate against him in federal court in the Northern District of California.
The criminal case
According to the Justice Department’s case page, a grand jury returned an indictment against Holmes and Balwani on June 14, 2018. Each faced two counts of conspiracy to commit wire fraud and nine counts of wire fraud. The indictment was superseded twice in July 2020, and the July 28, 2020 version is the operative one.
The two defendants were tried separately. At her trial, the jury returned its verdict on January 3, 2022. She was convicted of one count of conspiracy to commit wire fraud involving investors and three counts of wire fraud involving individual investors, covering more than $140 million in wire transfers. She was acquitted of the conspiracy count related to patients and of three counts of fraud against individual patients. The jury could not reach a unanimous verdict on three further investor counts, and one patient-related wire fraud count was dismissed during trial.
Judge Edward Davila sentenced Holmes on November 18, 2022 to 135 months (11 years and 3 months) in federal prison, followed by three years of supervised release. Balwani was sentenced on December 7, 2022 to 155 months (12 years and 11 months), also followed by three years of supervised release. The FDA, which investigated the case, reports that Balwani was found guilty of defrauding both investors and patients. Restitution hearings were still to be scheduled when the Justice Department page was last updated in December 2022, and this page does not state a final restitution figure.
What the record says about patients
The FDA’s account of its criminal investigation says Theranos representatives described a device that could run over a thousand tests, for conditions including cancer, diabetes and HIV, using only a few drops of blood. The same account describes patients whose results were later contradicted, for example a pregnant woman told she was miscarrying when she was not and a patient flagged as at risk for a heart attack whose hospital results were normal. Because she was acquitted of the patient-related counts, those accounts should be read as the FDA’s description of the investigation, not as a finding against her on those counts.
Lessons (editorial interpretation)
Everything above comes from public records. The section below is the editorial team’s interpretation, not a finding by any court or agency, and it makes no claim about what any individual knew or intended.
Private status means less outside checking. A public company files audited statements on a fixed schedule. A private company shares what it chooses with its investors. The SEC case concerned statements made to private investors, which shows how much of the verification burden sits with the people writing the check. Our guides to raising a seed round and to Canadian venture capital cover how rounds are normally diligenced.
Check each claim against operating data. The three SEC allegations are all checkable: what the device could actually test, who actually used it, and what revenue actually arrived. A projection above $100 million set against about $100,000 of actual revenue is a gap that a plain comparison of plan to actuals would show. The same discipline appears in top finance mistakes and in the notes on a startup financial dashboard.
Ask what the board of directors can actually verify. Commentators from NACD, Wharton and Yale have argued that the board and outside backers leaned on reputation and prominent names, and that governance and ethics questions went unasked. Those are opinions, and sources disagree about whether a different board would have changed the outcome. The practical takeaway is smaller: a director who cannot assess the core technology of a business benefits from an independent technical adviser, and a startup board benefits from members with industry experience. See startup board meetings for how oversight can be structured.
Voting control and preferences shape outcomes. The SEC settlement shows that super-voting shares and a liquidation preference determined who held control and who was paid first. Read both before signing. The founder equity guide and the valuation basics explain the terms.
Make independent verification routine. Founders who invite audits, reference calls and technical reviews make later disputes less likely, and investors who ask for them are following standard practice.
Frequently asked questions
How much money did Theranos raise? The SEC said more than $700 million, in its March 14, 2018 press release.
Was Elizabeth Holmes convicted? Yes, on four counts relating to investors, in a verdict on January 3, 2022. She was acquitted on counts relating to patients, according to the Justice Department.
Did the SEC case end in a trial? Holmes and Theranos settled without admitting or denying the allegations. The SEC said it would litigate against Balwani.
Sources and limits
- SEC, press release 2018-41, March 14, 2018 (sec.gov).
- U.S. Department of Justice, Northern District of California, case page “U.S. v. Elizabeth Holmes et al.,” last updated December 12, 2022 (justice.gov).
- U.S. Food and Drug Administration, “Patient Advocacy Lies at Heart of FDA Agent’s Theranos Case,” current as of December 2023 (fda.gov).
- Governance commentary used only for the framing of the lessons: NACD Directorship, Wharton Knowledge, Yale Insights, IMD (opinion pieces).
Limits: the Justice Department sentencing and verdict press release pages could not be retrieved in full, so figures come from the DOJ case page and the SEC release. Allegations in the SEC section are allegations, settled without admission. Restitution outcomes after December 2022 are not covered. Facts are as of November 2026 and later court filings may add to them.